{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:46Z","timestamp":1786649386020,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Ezrin, also known as cytovillin, is a member of the ERM family of protein. Ezrin cross-links actin filament with the plasma membrane. They are involved in the formation of microvilli, cell\u2013cell adhesion, maintenance of cell shape, cell motility, and membrane trafficking. Recent analysis reveals their involvement in signaling pathways. Ezrin is highly expressed in several types of human cancers, and correlation between its immunoreactivity and histopathological data as well as the patient outcome has previously been studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of the study was to analyze the immunohistochemical expression pattern of ezrin in oral potentially malignant disorders (OPMDs), namely, oral submucous fibrosis (OSMF) with different grades and clinically leucoplakia (hyperkeratosis with various degree of dysplasia) and its use as a predictive marker for malignant transformation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>\n                      Sample size\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 43, histopathologically confirmed cases of OPMDs (13 cases of OSMF with different grades and 30 cases of clinically leukoplakia) were retrieved from the Department of Oral and Maxillofacial Pathology. Immunohistochemistry was done using anti-ezrin antibody, and the expression was graded in terms of proportion and intensity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There was a significant expression of ezrin in OPMDs, and its cytoplasmic shift can be used as a predictive marker for malignant transformation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The findings of the current study revealed that the expression of ezrin in OPMDs may be related to the progression of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_139_17","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T06:36:24Z","timestamp":1513838184000},"page":"S205-S210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Immunohistochemical Expression Of Ezrin In Oral Potentially Malignant Disorders-A Descriptive Study"],"prefix":"10.4103","volume":"9","author":[{"given":"Raghini","family":"Mohanraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Ramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Premkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Natesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herald J.","family":"Sherlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheena","family":"Sukumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-41-20260427","first-page":"431246","article-title":"Oral carcinogenesis and oral cancer chemoprevention: A review","volume":"2011","author":"Tanaka","year":"2011","journal-title":"Patholog Res Int"},{"key":"R2-41-20260427","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4236\/jct.2012.34037","article-title":"Oral squamous cell carcinoma: Epidemiology, clinical presentation and treatment","volume":"3","author":"Feller","year":"2012","journal-title":"J Cancer Ther"},{"key":"R3-41-20260427","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1083\/jcb.126.6.1445","article-title":"Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family","volume":"126","author":"Turunen","year":"1994","journal-title":"J Cell Biol"},{"key":"R4-41-20260427","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1369\/0022155411418661","article-title":"Expression of Ezrin in Human Embryonic, Fetal, and Normal Adult Tissues","volume":"59","author":"Xie","year":"2011","journal-title":"Journal of Histochemistry and Cytochemistry"},{"key":"R5-41-20260427","doi-asserted-by":"crossref","first-page":"e68527","DOI":"10.1371\/journal.pone.0068527","article-title":"Prognostic value of ezrin in solid tumors: A meta-analysis of the literature","volume":"8","author":"Han","year":"2013","journal-title":"PLoS One"},{"key":"R6-41-20260427","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1471-2407-9-260","article-title":"Malignant transformation of oral potentially malignant disorders in males: A retrospective cohort study","volume":"9","author":"Ho","year":"2009","journal-title":"BMC Cancer"},{"key":"R7-41-20260427","doi-asserted-by":"crossref","first-page":"603740","DOI":"10.1155\/2011\/603740","article-title":"Understanding carcinogenesis for fighting oral cancer","volume":"2011","author":"Tanaka","year":"2011","journal-title":"J Oncol"},{"key":"R8-41-20260427","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/jso.21909","article-title":"Prognostic implication of ezrin expression in esophageal squamous cell carcinoma","volume":"104","author":"Xie","year":"2011","journal-title":"J Surg Oncol"},{"key":"R9-41-20260427","doi-asserted-by":"crossref","first-page":"e54881","DOI":"10.1371\/journal.pone.0054881","article-title":"Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma","volume":"8","author":"Saito","year":"2013","journal-title":"PLoS One"},{"key":"R10-41-20260427","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1349-7006.2009.01470.x","article-title":"Initiation of malignancy by duodenal contents reflux and the role of ezrin in developing esophageal squamous cell carcinoma","volume":"101","author":"Ling","year":"2010","journal-title":"Cancer Sci"},{"key":"R11-41-20260427","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/labinvest.3780174","article-title":"Altered expression of the ERM proteins in lung adenocarcinoma","volume":"80","author":"Tokunou","year":"2000","journal-title":"Lab Invest"},{"key":"R12-41-20260427","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0090-8258(03)00262-2","article-title":"Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients","volume":"90","author":"Moilanen","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R13-41-20260427","first-page":"245","article-title":"The prognostic values of the immunohistochemical expression of ezrin and large safety margins in basal cell carcinoma of the face","volume":"35","author":"Darwish","year":"2011","journal-title":"Egypt J PlastReconstr Surg"},{"key":"R14-41-20260427","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jmau.2014.04.001","article-title":"Prognostic value of ezrin expression in common epithelial tumors: An immunohistochemical study","volume":"2","author":"Gamei","year":"2014","journal-title":"J Microsc Ultrastruct"},{"key":"R15-41-20260427","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3109\/00016489.2012.758388","article-title":"Expression of HMGA1 and ezrin in laryngeal squamous cell carcinoma","volume":"133","author":"Wang","year":"2013","journal-title":"Acta Otolaryngol"},{"key":"R16-41-20260427","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5732\/cjc.009.10505","article-title":"Expression and clinical significance of ezrin and E-cadherin in esophageal squamous cell carcinoma","volume":"29","author":"Zhai","year":"2010","journal-title":"Chin J Cancer"},{"key":"R17-41-20260427","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/hed.20435","article-title":"Differential tissue and subcellular expressionof ERM proteins in normal and malignant tissues: Cytoplasmic ezrin expression has prognostic significance for head and neck squamous cell carcinoma","volume":"28","author":"Madan","year":"2006","journal-title":"Head Neck"},{"key":"R18-41-20260427","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12105-011-0328-1","article-title":"Cytoplasmic ezrin and moesin correlate with poor survival in head and neck squamous cell carcinoma","volume":"6","author":"Schlecht","year":"2012","journal-title":"Head Neck Pathol"},{"key":"R19-41-20260427","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1369\/jhc.5A6881.2006","article-title":"Altered expression of ezrin in esophageal squamous cell carcinoma","volume":"54","author":"Zeng","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"R20-41-20260427","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/ijc.24216","article-title":"Roles of ezrin in the growth and invasiveness of esophageal squamous carcinoma cells","volume":"124","author":"Xie","year":"2009","journal-title":"Int J Cancer"},{"key":"R21-41-20260427","doi-asserted-by":"crossref","first-page":"e50710","DOI":"10.1371\/journal.pone.0050710","article-title":"Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01438291-201709001-00041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:53:27Z","timestamp":1786647207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01438291-201709001-00041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_139_17","relation":{},"ISSN":["0976-4879"],"issn-type":[{"value":"0976-4879","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}